About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Report Type
Organization
Disposition
Year
Month
Found 45628 record(s)
Req # A-2020-001512
Adverse Drug Reactions (ADRs). Report numbers: E2B_03020957, E2B_03022194, E2B_03022481, E2B_03023411, E2B_03023680, E2B_03024602, E2B_03025480, E2B_03027899, E2B_03027935, E2B_03027941, E2B_03027953, E2B_03027961, E2B_03028067, E2B_03028400,…Organization: Health Canada
February 2025
Req # A-2021-000115
Adverse Drug Reactions (ADRs) for Celexa. Report numbers: 916050, 914287, E2B_03195941, E2B_03266230, 920937, E2B_03306917, 919838, 920655. ADRs for Clopixol. Report numbers: 917413, 920812. ADRs for Fluanxol. Report numbers: 913790, 913799,…Organization: Health Canada
February 2025
Req # A-2021-000378
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 21-102437-273.Organization: Health Canada
February 2025
Req # A-2021-000926
Adverse Drug Reaction (ADR) for NITROGLYCERIN. Report number: E2B_03716623.Organization: Health Canada
February 2025
Req # A-2021-002062
Adverse Drug Reactions (ADRs) for RANITIDINE, BISACODYL, METFORMIN HYDROCHLORIDE. Report numbers: E2B_04715303, E2B_04820013, E2B_04836873, 000971689, 000969507, E2B_04692702, 000976606, E2B_04771838, 000969694, E2B_04679069.Organization: Health Canada
February 2025
Req # A-2021-002090
Adverse Drug Reactions (ADRs). Report numbers: E2B_04514095, E2B_04617115, E2B_04586024, E2B_04567305, E2B_04514226, E2B_04594271, E2B_04595151, E2B_04596448, E2B_04595171, E2B_04554222, E2B_04595269, E2B_04595132, E2B_04595165, E2B_04588479, 965792…Organization: Health Canada
February 2025
Req # A-2022-000187
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 21-119257-302.Organization: Health Canada
February 2025
Req # A-2022-000765
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 22-107275-132.Organization: Health Canada
February 2025
Req # A-2022-001320
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 22-112492-988.Organization: Health Canada
February 2025
Req # A-2022-001361
Adverse Drug Reactions (ADRs). Report numbers: E2B_05801979, E2B_05801982, E2B_05801988, E2B_05801990, E2B_05802004, E2B_05802007, E2B_05802044, E2B_05802055, E2B_05802068, E2B_05802084.Organization: Health Canada
February 2025